MarketMoodz
Wells Fargo Downgrades Sherwin-Williams to Equal-Weight; PT at $365
Wells Fargo downgraded Sherwin-Williams (SHW) to equal-weight from overweight and cut the price target to $365, citing rising coatings raw-material costs tied to the Iran conflict. The move signals near-term margin pressure as macro headwinds threaten demand in housing, auto, and industrial markets.
Key Takeaways
- Price target cut to $365 from $410, implying about 8.7% upside from the prior close.
- Downgrade to equal-weight due to expected margin pressure from higher raw-material costs linked to the Iran conflict.
- Macro headwinds from the Iran conflict could persist for 3–4 months or longer, weighing on revenue growth.
- Axalta Coating Systems downgraded to equal-weight from overweight in the same note.
People Involved
- Michael Sison Wells Fargo Securities Equity Research Analyst
Entities Involved
- Sherwin-Williams Co. (SHW) Paints and coatings manufacturer
- Wells Fargo & Co. Brokerage/Investment bank issuing the downgrade
- Axalta Coating Systems Ltd. (AXTA) Coating systems company downgraded by Wells Fargo
MarketMoodz Analysis
For investors, the downgrade reframes the near-term earnings outlook for SHW as margins come under pressure from rising coatings raw-material costs, a trend Wells Fargo links to the Iran conflict and broader inflation in inputs. The price-target cut to $365 leaves little room for missteps if costs don’t ease, even as the stock trades with ~8.7% potential upside from the prior close.
Historically, coatings peers have struggled when input costs spike, with margins compressing before price increases fully pass through. The divergence between Wells Fargo’s view and the current consensus (16 of 27 analysts rated Buy or Strong Buy per LSEG) highlights a potential near-term catalyst risk for SHW if macro headwinds persist longer than expected and demand cools in housing, autos, and industrial production.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial